Af­ter cross­ing t's, dot­ting i's, Im­muno­core nails down break­through ther­a­py des­ig­na­tion for lead TCR ther­a­py

Days af­ter tap­ping a new com­mer­cial head, Im­muno­core has scored a break­through ther­a­py des­ig­na­tion for its lead T cell re­cep­tor pro­gram, which it plans on punt­ing to reg­u­la­tors for a speedy con­sid­er­a­tion in un­re­sectable or metasta­t­ic uveal car­ci­no­ma lat­er this year.

CEO Bahi­ja Jal­lal has al­ready nailed down $175 mil­lion to back a po­ten­tial launch for tebenta­fusp, and ear­li­er this week she tapped As­traZeneca vet Ralph Tor­bay to lead the charge. The com­pa­ny will ap­proach reg­u­la­tors in Q3, it an­nounced on Fri­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER